prednisone has been researched along with African Lymphoma in 191 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An increased risk of lymphoproliferative disorders (LPD) has been demonstrated in patients treated with methotrexate (MTX) for rheumatoid arthritis (RA)." | 7.83 | [Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis]. ( Iwashige, A; Katsuragi, T; Tsukada, J, 2016) |
| " In this case report, we treated a 20-year-old male patient with cyclophosphamide, doxorubicin, vincristine, dexamethasone, and methotrexate and cytarabine chemotherapy following a diagnosis of Stage IV Burkitt lymphoma." | 4.89 | Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma. ( Choi, KH; Hyun, JY; Kim, JH; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, JY; Lim, SH, 2013) |
| "Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)." | 4.12 | Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. ( Allione, B; Angelillo, P; Cattaneo, C; Erbella, F; Facchetti, F; Ferreri, AJM; Flospergher, E; Foppoli, M; Lleshi, A; Pagani, C; Pecciarini, L; Ponzoni, M; Re, A; Rossi, G; Sassone, M; Spina, M; Steffanoni, S; Verga, L, 2022) |
| "The hyper-CVAD/methotrexate-cytarabine (H-CVAD/ MTX-AraC) chemotherapy protocol has been one of the standard treatments for hematological malignancies, such as mantle cell lymphoma (MCL), Burkitt lymphoma (BL), and B-cell and T-cell acute lymphoblastic leukemia." | 4.02 | Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL. ( Algarra-Algarra, JL; Gómez-Catalán, I; Hernández-Fernández, F; Ibañez-García, Á; Marín-Sánchez, A; Martínez-Fernández, G; Montoya-Morcillo, MC; Romero-Macías, JR, 2021) |
| "An increased risk of lymphoproliferative disorders (LPD) has been demonstrated in patients treated with methotrexate (MTX) for rheumatoid arthritis (RA)." | 3.83 | [Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis]. ( Iwashige, A; Katsuragi, T; Tsukada, J, 2016) |
| " We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy." | 3.74 | Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. ( Bergsagel, DJ; Crosswell, HE; Lew, G; Yost, R, 2008) |
| "Between June 1979 and June 1984 18 adult patients with small noncleaved cell lymphoma (SNCL) (diffuse undifferentiated lymphoma, Burkitt's and non-Burkitt's types of the Rappaport classification) were treated with high-dose cyclophosphamide, doxorubicin, vincristine, prednisone, midcycle high-dose methotrexate, and intrathecal methotrexate." | 3.67 | Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). ( Bernstein, JI; Coleman, CN; Dorfman, RF; Rosenberg, SA; Strickler, JG, 1986) |
| "Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone." | 2.79 | Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. ( Anderson, JR; Barth, M; Cairo, MS; Frazer, JK; Galardy, P; Goldman, S; Gross, TG; Harrison, L; Perkins, SL; Sanger, W; Shiramizu, B; Smith, L; Weinstein, H, 2014) |
| "Older patients with Burkitt lymphoma/leukemia (BL) have inferior outcomes." | 2.78 | Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. ( Ambinder, RF; Bolaños-Meade, J; Borowitz, MJ; Brodsky, RA; Carraway, HE; Cho, SY; Crilley, PA; Gladstone, DE; Huff, CA; Jones, RJ; Kasamon, YL; Matsui, WH; Smith, BD; Swinnen, LJ; Tsai, HL, 2013) |
| "Burkitt's lymphoma is an aggressive B-cell lymphoma that occurs in children and adults and is largely curable with the use of intensive and toxic chemotherapy." | 2.78 | Low-intensity therapy in adults with Burkitt's lymphoma. ( Cole, D; Dunleavy, K; Grant, C; Jaffe, ES; Little, RF; Pittaluga, S; Shovlin, M; Staudt, LM; Steinberg, SM; Widemann, B; Wilson, WH, 2013) |
| "Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL)." | 2.72 | Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. ( Guan, ZZ; He, YJ; Lin, JY; Lui, DG; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden." | 2.71 | Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. ( Bosq, J; Casassus, P; Diviné, M; Dupriez, B; Koscielny, S; Le Maignan, C; Pico, JL; Raphaël, M; Ribrag, V; Sebban, C; Stamattoulas, A, 2005) |
| "We concluded that adult patients with undifferentiated lymphomas could be treated successfully with an aggressive multi-drug chemotherapy regimen, consisting of multiple alternating cycles of non-crossed-resistant chemotherapy." | 2.68 | Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's undifferentiated lymphoma. ( Andersen, JW; Hines, JD; Mann, R; Mazza, JJ; Neiman, RS; O'Connell, MJ; Oken, MM, 1995) |
| "A total of 119 children (1990-95) with acute lymphoblastic leukemia (ALL) B-lineage either CD10+ or CD10- were registered into a single non-randomized chemotherapy protocol." | 2.68 | B-lineage acute lymphoblastic leukemia of childhood. An institutional experience. ( Cardenas-Cardos, R; Gómez-Martínez, R; Leal-Leal, C; Meza-Coria, C; Navarro-Alegría, I; Rivera-Luna, R; Vega-Vega, L, 1997) |
| "Burkitt lymphoma is a fast-growing high grade B-cell neoplasm that rarely affects adults." | 2.50 | Adult abdominal Burkitt lymphoma with isolated peritoneal involvement. ( Catarino, R; Estevão, A; Matos, H; Oliveira, C; Serra, P, 2014) |
| "Diffuse large B-cell lymphoma and Burkitt lymphoma are two distinct lymphoma entities recognized by the current World Health Organization classification of lymphoid neoplasms." | 2.48 | New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. ( Dörken, B; Frick, M; Lenz, G, 2012) |
| "Burkitt lymphoma is a unique B-cell malignancy with a high proliferation rate and characteristic genetic changes involving the c-myc oncogene." | 2.44 | Adult Burkitt lymphoma: advances in diagnosis and treatment. ( Aldoss, IT; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Fu, K; Vose, JM; Weisenburger, DD, 2008) |
| "A Japanese case of Burkitt's lymphoma is presented." | 2.40 | Burkitt's lymphoma involving the mandible: report of a case and review of Japanese cases. ( Hanazawa, T; Kimura, Y; Nagumo, M; Okano, T; Sakamaki, H; Yamaguchi, A, 1998) |
| "We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease." | 2.39 | Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996) |
| "Burkitt tumors are malignant lymphoblastic lymphomas occurring predominantly in Africa in children and young adults and involving in many cases the intestinal tract; these tumors occur rather seldom outside Africa." | 2.36 | [Isolated tumor of the rectum as primary manifestation of Burkitt lymphoma (author's transl)]. ( Döhnert, G; Feltkamp, H; Lang, R; Mies, R; Mödder, B; Stock, W; Thiele, KG, 1981) |
| "Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens." | 1.56 | Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. ( Abramson, JS; Bartlett, NL; Bierman, PJ; Dunleavy, K; Fanale, MA; Friedberg, JW; Hanna, WT; Jaffe, ES; Jagadeesh, D; Kahl, BS; Link, BK; Little, RF; Lucas, AN; Melani, C; Mitsuyasu, RT; Noy, A; Patel, P; Peace, D; Pittaluga, S; Powell, BL; Roschewski, M; Steinberg, SM; Watson, PR; Wilson, WH, 2020) |
| "Pediatric Burkitt lymphoma has historically been treated with intensive methotrexate-based chemotherapy, which improves patient survival while causing severe toxicities." | 1.51 | Successful Use of EPOCH-R in 2 Young Adult Patients With Burkitt Lymphoma and Acute Kidney Injury: A Case Report. ( Eisenman, K; Maloney, KW; Ross, S, 2019) |
| "Skin involvement in Burkitt's lymphoma (BL) is rare, more so in the pediatric age group." | 1.48 | Skin involvement in Burkitt's lymphoma. ( Lipi, L; Misra, R; Thakkar, D; Yadav, SP, 2018) |
| "The diagnosis of stage IV Burkitt lymphoma with predominant extranodal cardiac involvement was withheld wherefore promptly aggressive therapy was started according to the GMALL B-NHL86 protocol." | 1.46 | Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy? ( De Pauw, M; Demulier, L; Steel, E; Terryn, W; Vandekerckhove, L; Vercammen, J; Vervloet, DM, 2017) |
| "(2) Burkitt's lymphoma was the most common (34/43, 79." | 1.43 | [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia]. ( Gao, J; Guo, J; Guo, X; Jia, CS; Li, Q; Zhou, CY; Zhu, YP, 2016) |
| "Among these patients, 7 had Burkitt lymphoma (BL), 20 had diffuse large B cell lymphoma (DLBCL), 7 had plasmablastic lymphoma (PL), and 1 had primary effusion lymphoma (PEL)." | 1.40 | Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era. ( Adamski, M; Gunthel, C; Mosunjac, M; Nguyen, ML; Silverton, A, 2014) |
| "In the largest adult case series in Burkitt-PTLD to date, sequential immunochemotherapy with rituximab followed by standard CHOP or R-CHOP was a both safe and effective treatment." | 1.38 | Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis ( Anagnostopoulos, I; Atta, J; Gärtner, B; Lehmkuhl, H; Lenze, D; Neuhaus, R; Oertel, S; Planker, M; Reinke, P; Riess, H; Trappe, RU; Zimmermann, H, 2012) |
| "AIDS-related Burkitt's lymphoma or leukemia (BLL) is increasingly treated with specific and intensive multiagent schedules." | 1.37 | Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. ( Brunet, S; de la Torre, J; Esteve, J; Hoelzer, D; La Cruz, J; Mahillo, B; Miralles, P; Morgades, M; Oriol, A; Ribera, JM; Téllez, MJ; Valencia, E; Xicoy, B, 2011) |
| "Burkitt's lymphoma is not an uncommon malignancy in the paediatric population." | 1.36 | Burkitt's lymphoma in a young Brazilian boy. ( Botelho, Tde L; Lopes, AP; Meneghini, AJ; Monteiro, MC; Pereira, CM; Silva, GB, 2010) |
| "Eight patients had Burkitt lymphoma and three had Burkitt leukemia; their median age was 48 years." | 1.35 | Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. ( Choi, KA; Huh, W; Kim, DJ; Kim, K; Kim, WS; Kim, YG; Ko, YH; Lee, JE; Oh, HY, 2009) |
| "A 35-year old woman developed Burkitt's lymphoma and was treated with rituximab and CHOP therapy early during pregnancy." | 1.33 | The effects of rituximab treatment during pregnancy on a neonate. ( Friedrichs, B; Salwender, H; Schmitz, N; Tiemann, M; Verpoort, K; Wenger, MK, 2006) |
| "African Burkitt lymphoma with abdominal "bulky" involvement was strongly suspected." | 1.32 | African Burkitt lymphoma successfully treated with CEOP polychemotherapy. ( Balzarini, L; Bregani, ER; Cabibbe, M, 2004) |
| "The incidence of Burkitt's lymphoma was higher during the dry season and the period of high malaria transmission (p < 0." | 1.31 | Epidemiology of Burkitt's lymphoma in Enugu, Nigeria. ( Emodi, I; Kaine, W; Oguonu, T, 2002) |
| "Burkitt's lymphoma is a rare aggressive lymphoma, which responds poorly to standard chemotherapy regimens used to treat high-grade non-Hodgkin's lymphoma (NHL)." | 1.31 | Burkitt's lymphoma: single-centre experience with modified BFM protocol. ( Harris, E; Jackson, N; Jones, L; Mahendra, P; Paneesha, S, 2002) |
| "Acute liver failure is rarely secondary to lymphoma or leukaemia and it is extremely uncommon as the initial presentation of malignancy." | 1.30 | Severe acute liver failure as the initial manifestation of haematological malignancy. ( Camacho, E; Donato, A; Ferreira, M; Figueiredo, P; Freitas, D; Romãozinho, JM; Sousa, I; Souto, P, 1997) |
| "Lymphoblastic lymphoma (LBL) and Burkitt's lymphoma belong to the very aggressive lymphomas requiring intensive therapy." | 1.30 | Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients. ( Havemann, K; Kaiser, U; Uebelacker, I, 1999) |
| "After confirming the diagnosis of Burkitt's lymphoma, they were treated according to conventional protocols, with no need to reduce the dose intensity." | 1.29 | Favorable response of pediatric AIDS-related Burkitt's lymphoma treated by aggressive chemotherapy. ( Ben-Bassat, I; Mandel, M; Martinowitz, U; Neumann, Y; Ramot, B; Rechavi, G; Toren, A; Varon, D, 1993) |
| "An African Burkitt's lymphoma occurred in a 9-year-old American boy who had jaw tumors, proptosis, and abdominal masses." | 1.28 | African Burkitt's lymphoma: case report and light and electron microscopic findings. ( Bartley, MH; Meshul, CK; Myers, SL; Yih, WY, 1990) |
| "The development of Kaposi's sarcoma has been associated with either iatrogenic or disease-related immunodeficiency." | 1.27 | Steroid-related development of Kaposi's sarcoma in a homosexual man with Burkitt's lymphoma. ( Koziner, B; Krown, SE; Real, FX, 1986) |
| "High-grade malignant lymphomas have to be treated with agressive combination chemotherapy in order to get the patient into complete remission with the possibility for a long relapse-free interval." | 1.26 | [Chemotherapy in non-Hodgkin's lymphomas (author's transl)]. ( Schmidt, CG, 1977) |
| "A case of histopathologically proven Burkitt's lymphoma is described with special reference to clinical, serological and immunological features." | 1.26 | [The so-called white Burkitt's lymphoma]. ( Hartmann, D; Obrecht, JP; Wegmann, W, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (23.04) | 18.7374 |
| 1990's | 32 (16.75) | 18.2507 |
| 2000's | 52 (27.23) | 29.6817 |
| 2010's | 49 (25.65) | 24.3611 |
| 2020's | 14 (7.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, A | 2 |
| Arun, VA | 1 |
| Bal, A | 1 |
| Malhotra, P | 2 |
| Ferreri, AJM | 1 |
| Angelillo, P | 1 |
| Erbella, F | 1 |
| Cattaneo, C | 1 |
| Verga, L | 1 |
| Lleshi, A | 1 |
| Allione, B | 1 |
| Ponzoni, M | 1 |
| Facchetti, F | 1 |
| Pagani, C | 1 |
| Foppoli, M | 1 |
| Pecciarini, L | 1 |
| Sassone, M | 1 |
| Steffanoni, S | 1 |
| Flospergher, E | 1 |
| Rossi, G | 1 |
| Spina, M | 1 |
| Re, A | 1 |
| Afify, Z | 3 |
| Orjuela-Grimm, M | 3 |
| Smith, CM | 3 |
| Dalal, M | 3 |
| Ford, JB | 3 |
| Pillai, P | 3 |
| Robles, JM | 3 |
| Reddy, S | 3 |
| McCormack, S | 3 |
| Ehrhardt, MJ | 3 |
| Ureda, T | 3 |
| Alperstein, W | 3 |
| Edington, H | 3 |
| Miller, TP | 3 |
| Rubinstein, JD | 3 |
| Kavanaugh, M | 3 |
| Bukowinski, AJ | 3 |
| Friehling, E | 3 |
| Rivers, JM | 3 |
| Chisholm, KM | 3 |
| Marks, LJ | 3 |
| Mason, CC | 3 |
| Lim, KJC | 1 |
| Filshie, R | 1 |
| Sun, S | 1 |
| Xu, B | 1 |
| Zhang, Q | 1 |
| Zhao, CS | 1 |
| Ma, R | 1 |
| He, J | 1 |
| Zhang, Y | 1 |
| Speckhart, BA | 1 |
| Bugaieski, E | 1 |
| Antony, R | 1 |
| Fernandez, KS | 1 |
| Roschewski, M | 2 |
| Dunleavy, K | 3 |
| Abramson, JS | 2 |
| Powell, BL | 1 |
| Link, BK | 1 |
| Patel, P | 1 |
| Bierman, PJ | 3 |
| Jagadeesh, D | 1 |
| Mitsuyasu, RT | 1 |
| Peace, D | 1 |
| Watson, PR | 1 |
| Hanna, WT | 1 |
| Melani, C | 1 |
| Lucas, AN | 1 |
| Steinberg, SM | 2 |
| Pittaluga, S | 2 |
| Jaffe, ES | 2 |
| Friedberg, JW | 1 |
| Kahl, BS | 2 |
| Little, RF | 2 |
| Bartlett, NL | 1 |
| Fanale, MA | 1 |
| Noy, A | 1 |
| Wilson, WH | 3 |
| McMillan, AK | 1 |
| Phillips, EH | 1 |
| Kirkwood, AA | 1 |
| Barrans, S | 1 |
| Burton, C | 1 |
| Rule, S | 1 |
| Patmore, R | 1 |
| Pettengell, R | 1 |
| Ardeshna, KM | 1 |
| Lawrie, A | 1 |
| Montoto, S | 1 |
| Paneesha, S | 2 |
| Clifton-Hadley, L | 1 |
| Linch, DC | 1 |
| Jindal, N | 1 |
| Lad, D | 1 |
| Prakash, G | 1 |
| Khadwal, A | 1 |
| Hertzberg, M | 1 |
| Joske, DJL | 1 |
| Gandhi, MK | 1 |
| Chauhan, P | 1 |
| Gupta, A | 1 |
| Mandelia, A | 1 |
| Yadav, S | 1 |
| Rahman, K | 1 |
| Nityanand, S | 1 |
| Marín-Sánchez, A | 1 |
| Martínez-Fernández, G | 1 |
| Gómez-Catalán, I | 1 |
| Montoya-Morcillo, MC | 1 |
| Algarra-Algarra, JL | 1 |
| Ibañez-García, Á | 1 |
| Hernández-Fernández, F | 1 |
| Romero-Macías, JR | 1 |
| Vural, S | 1 |
| Genç, DB | 1 |
| Kebudi, R | 1 |
| Doğan, Ö | 1 |
| Karaman, S | 2 |
| Xiao, J | 1 |
| Du, S | 1 |
| Dai, G | 1 |
| Gao, G | 1 |
| Yang, D | 1 |
| Zhao, H | 1 |
| Hunter, NB | 1 |
| Vogt, S | 1 |
| Ambinder, RF | 2 |
| Thakkar, D | 1 |
| Lipi, L | 1 |
| Misra, R | 1 |
| Yadav, SP | 1 |
| Ross, S | 1 |
| Eisenman, K | 1 |
| Maloney, KW | 1 |
| Bobillo, S | 1 |
| Abrisqueta, P | 1 |
| Sánchez-González, B | 1 |
| Giné, E | 1 |
| Romero, S | 1 |
| Alcoceba, M | 1 |
| González-Barca, E | 1 |
| González de Villambrosía, S | 1 |
| Sancho, JM | 1 |
| Gómez, P | 1 |
| Bento, L | 1 |
| Montoro, J | 1 |
| Montes, S | 1 |
| López, A | 1 |
| Bosch, F | 1 |
| Painschab, MS | 1 |
| Westmoreland, KD | 2 |
| Kasonkanji, E | 2 |
| Zuze, T | 1 |
| Kaimila, B | 2 |
| Waswa, P | 1 |
| El-Mallawany, NK | 2 |
| Tomoka, T | 1 |
| Mulenga, M | 1 |
| Montgomery, ND | 2 |
| Fedoriw, Y | 2 |
| Gopal, S | 2 |
| Nitta, H | 1 |
| Lim, SH | 1 |
| Lee, JY | 2 |
| Kim, JH | 1 |
| Choi, KH | 1 |
| Hyun, JY | 1 |
| Ko, YH | 3 |
| Lee, J | 1 |
| Kim, SJ | 2 |
| Kim, WS | 3 |
| Aurer, I | 1 |
| Bašić-Kinda, S | 1 |
| Radman, I | 1 |
| Ilić, I | 1 |
| Grah, JJ | 1 |
| Valencia-Hipόlito, A | 1 |
| Hernández-Atenógenes, M | 1 |
| Vega, GG | 1 |
| Maldonado-Valenzuela, A | 1 |
| Ramon, G | 1 |
| Mayani, H | 1 |
| Peña Alonso, Y | 1 |
| Martinez-Maza, O | 1 |
| Méndez-Tenorio, A | 1 |
| Huerta-Yepez, S | 1 |
| Bonavida, B | 1 |
| Vega, MI | 1 |
| Iványi, JL | 1 |
| Marton, E | 1 |
| Plander, M | 1 |
| Engert, ZV | 1 |
| Tóth, C | 1 |
| Shovlin, M | 1 |
| Cole, D | 1 |
| Grant, C | 1 |
| Widemann, B | 1 |
| Staudt, LM | 1 |
| Luo, DL | 1 |
| Liu, YH | 1 |
| Zhang, F | 1 |
| Xu, FP | 1 |
| Yan, LX | 1 |
| Chen, J | 1 |
| Xu, J | 1 |
| Luo, XL | 1 |
| Zhuang, HG | 1 |
| Doycheva, I | 1 |
| Tanner, S | 1 |
| Zhou, D | 1 |
| Samadder, NJ | 1 |
| Rong, YF | 1 |
| He, LM | 1 |
| Zhang, YS | 1 |
| Feng, YZ | 1 |
| Kojima, Y | 1 |
| Hagiwara, S | 1 |
| Uehira, T | 1 |
| Ajisawa, A | 1 |
| Kitanaka, A | 1 |
| Tanuma, J | 1 |
| Okada, S | 2 |
| Nagai, H | 1 |
| Ramanathan, A | 1 |
| Mahmoud, HA | 1 |
| Hui, LP | 1 |
| Mei, NY | 1 |
| Valliappan, V | 1 |
| Zain, RB | 1 |
| Silverton, A | 1 |
| Gunthel, C | 1 |
| Adamski, M | 1 |
| Mosunjac, M | 1 |
| Nguyen, ML | 1 |
| Oliveira, C | 1 |
| Matos, H | 1 |
| Serra, P | 1 |
| Catarino, R | 1 |
| Estevão, A | 1 |
| Rohde, M | 1 |
| Richter, J | 1 |
| Schlesner, M | 1 |
| Betts, MJ | 1 |
| Claviez, A | 1 |
| Bonn, BR | 1 |
| Zimmermann, M | 1 |
| Damm-Welk, C | 1 |
| Russell, RB | 1 |
| Borkhardt, A | 1 |
| Eils, R | 1 |
| Hoell, JI | 1 |
| Szczepanowski, M | 1 |
| Oschlies, I | 1 |
| Klapper, W | 1 |
| Burkhardt, B | 1 |
| Siebert, R | 1 |
| Goldman, S | 1 |
| Smith, L | 1 |
| Galardy, P | 1 |
| Perkins, SL | 2 |
| Frazer, JK | 1 |
| Sanger, W | 1 |
| Anderson, JR | 3 |
| Gross, TG | 1 |
| Weinstein, H | 1 |
| Harrison, L | 1 |
| Shiramizu, B | 1 |
| Barth, M | 1 |
| Cairo, MS | 2 |
| Jacobson, C | 1 |
| LaCasce, A | 1 |
| Maruyama, D | 1 |
| Carey, CD | 1 |
| Gusenleitner, D | 1 |
| Chapuy, B | 1 |
| Kovach, AE | 1 |
| Kluk, MJ | 1 |
| Sun, HH | 1 |
| Crossland, RE | 1 |
| Bacon, CM | 1 |
| Rand, V | 1 |
| Dal Cin, P | 1 |
| Le, LP | 1 |
| Neuberg, D | 1 |
| Sohani, AR | 2 |
| Shipp, MA | 1 |
| Monti, S | 1 |
| Rodig, SJ | 1 |
| Hoelzer, D | 4 |
| Johnson, DH | 1 |
| Reske, T | 1 |
| Ruiz, M | 1 |
| Zhang, S | 1 |
| Wilson, D | 1 |
| Czader, M | 1 |
| Ferreiro, JF | 1 |
| Morscio, J | 1 |
| Dierickx, D | 1 |
| Marcelis, L | 1 |
| Verhoef, G | 1 |
| Vandenberghe, P | 1 |
| Tousseyn, T | 1 |
| Wlodarska, I | 1 |
| Landsburg, DJ | 1 |
| Petrich, AM | 1 |
| Press, O | 1 |
| Cassaday, R | 1 |
| Chavez, JC | 1 |
| Song, K | 1 |
| Zelenetz, AD | 1 |
| Gandhi, M | 1 |
| Shah, N | 1 |
| Fenske, TS | 1 |
| Jaso, J | 1 |
| Medeiros, LJ | 1 |
| Yang, DT | 1 |
| Nabhan, C | 1 |
| Katsuragi, T | 1 |
| Iwashige, A | 1 |
| Tsukada, J | 1 |
| Guo, J | 1 |
| Zhu, YP | 1 |
| Gao, J | 1 |
| Li, Q | 1 |
| Jia, CS | 1 |
| Zhou, CY | 1 |
| Guo, X | 1 |
| Stanley, CC | 1 |
| Heimlich, BJ | 1 |
| Wasswa, P | 1 |
| Mtete, I | 1 |
| Butia, M | 1 |
| Itimu, S | 1 |
| Chasela, M | 1 |
| Mtunda, M | 1 |
| Chikasema, M | 1 |
| Makwakwa, V | 1 |
| Chimzimu, F | 1 |
| Kampani, C | 1 |
| Dhungel, BM | 1 |
| Krysiak, R | 1 |
| Rosenberg, NE | 1 |
| Liomba, NG | 1 |
| Ribrag, V | 2 |
| Koscielny, S | 2 |
| Bosq, J | 2 |
| Leguay, T | 1 |
| Casasnovas, O | 1 |
| Fornecker, LM | 1 |
| Recher, C | 1 |
| Ghesquieres, H | 1 |
| Morschhauser, F | 1 |
| Girault, S | 1 |
| Le Gouill, S | 1 |
| Ojeda-Uribe, M | 1 |
| Mariette, C | 1 |
| Cornillon, J | 1 |
| Cartron, G | 1 |
| Verge, V | 1 |
| Chassagne-Clément, C | 1 |
| Dombret, H | 1 |
| Coiffier, B | 1 |
| Lamy, T | 1 |
| Tilly, H | 2 |
| Salles, G | 1 |
| Vervloet, DM | 1 |
| De Pauw, M | 1 |
| Demulier, L | 1 |
| Vercammen, J | 1 |
| Terryn, W | 1 |
| Steel, E | 1 |
| Vandekerckhove, L | 1 |
| Chan, TS | 1 |
| Khong, PL | 1 |
| Kwong, YL | 1 |
| Khan, U | 1 |
| Dul, C | 1 |
| Bhagat, VH | 1 |
| Sepe, T | 1 |
| Short, NJ | 1 |
| Kantarjian, HM | 1 |
| Ko, H | 1 |
| Khoury, JD | 1 |
| Ravandi, F | 1 |
| Thomas, DA | 1 |
| Garcia-Manero, G | 1 |
| Khouri, M | 1 |
| Cortes, JE | 1 |
| Wierda, WG | 1 |
| Verstovsek, S | 1 |
| Estrov, Z | 1 |
| Ferrajoli, A | 1 |
| Thompson, PA | 1 |
| Pierce, S | 1 |
| O'Brien, SM | 1 |
| Jabbour, E | 1 |
| Nomura, Y | 1 |
| Yoshida, S | 2 |
| Karube, K | 1 |
| Takeshita, M | 1 |
| Hirose, S | 1 |
| Nakamura, S | 1 |
| Yoshino, T | 1 |
| Kikuchi, M | 1 |
| Ohshima, K | 1 |
| Zvonkov, EE | 3 |
| Kremenetskaia, AM | 3 |
| Kravchenko, SK | 3 |
| Makhinia, VA | 2 |
| Kaplanskaia, IB | 3 |
| Obukhova, TN | 3 |
| Samoĭlova, RS | 3 |
| Shevelev, AA | 1 |
| Magomedova, AU | 3 |
| Bariakh, EA | 2 |
| Krasil'nikova, BB | 3 |
| Gubkin, AV | 1 |
| Iliushkina, EA | 1 |
| Mar'in, DS | 2 |
| Morozova, AK | 1 |
| Kulikov, SM | 1 |
| Gemdzhian, EG | 1 |
| Vorob'ev, AI | 2 |
| Choi, KA | 1 |
| Lee, JE | 1 |
| Kim, YG | 1 |
| Kim, DJ | 1 |
| Kim, K | 2 |
| Oh, HY | 1 |
| Huh, W | 1 |
| Aldoss, IT | 1 |
| Weisenburger, DD | 1 |
| Fu, K | 1 |
| Chan, WC | 1 |
| Vose, JM | 1 |
| Bociek, RG | 1 |
| Armitage, JO | 2 |
| Choi, MK | 1 |
| Jun, HJ | 1 |
| Lee, SY | 1 |
| Kim, KH | 1 |
| Lim, DH | 1 |
| Suzuki, K | 1 |
| Nakazato, T | 1 |
| Sanada, Y | 1 |
| Mihara, A | 1 |
| Tachikawa, N | 1 |
| Kurai, H | 1 |
| Yoshimura, Y | 1 |
| Hayashi, H | 1 |
| Kakimoto, T | 1 |
| Pereira, CM | 1 |
| Lopes, AP | 1 |
| Meneghini, AJ | 1 |
| Silva, GB | 1 |
| Monteiro, MC | 1 |
| Botelho, Tde L | 1 |
| Celkan, TT | 1 |
| Bariş, S | 1 |
| Ozdemir, N | 1 |
| Ozkan, A | 1 |
| Apak, H | 1 |
| Doğru, O | 1 |
| Canbolat, A | 1 |
| Ozdil, M | 1 |
| Aki, H | 1 |
| Adaletli, I | 1 |
| Kurugoglu, S | 1 |
| Hallac, M | 1 |
| Yildiz, I | 1 |
| Green, HL | 1 |
| Rytting, ME | 1 |
| Cox, CS | 1 |
| Xicoy, B | 2 |
| Ribera, JM | 2 |
| Miralles, P | 1 |
| La Cruz, J | 1 |
| Oriol, A | 1 |
| Valencia, E | 1 |
| Morgades, M | 1 |
| Mahillo, B | 1 |
| de la Torre, J | 1 |
| Téllez, MJ | 1 |
| Brunet, S | 2 |
| Esteve, J | 2 |
| Goto, M | 1 |
| Onizawa, K | 1 |
| Yanagawa, T | 1 |
| Yamagata, K | 1 |
| Shinozuka, K | 1 |
| Nishikii, H | 1 |
| Koganemaru, H | 1 |
| Chiba, S | 1 |
| Bukawa, H | 1 |
| Zimmermann, H | 1 |
| Reinke, P | 1 |
| Neuhaus, R | 1 |
| Lehmkuhl, H | 1 |
| Oertel, S | 1 |
| Atta, J | 1 |
| Planker, M | 1 |
| Gärtner, B | 1 |
| Lenze, D | 1 |
| Anagnostopoulos, I | 1 |
| Riess, H | 1 |
| Trappe, RU | 1 |
| Frick, M | 1 |
| Dörken, B | 1 |
| Lenz, G | 1 |
| Kaplan, LD | 1 |
| Huang, H | 1 |
| Yang, WP | 1 |
| Xu, HY | 1 |
| Kasamon, YL | 1 |
| Brodsky, RA | 1 |
| Borowitz, MJ | 1 |
| Crilley, PA | 1 |
| Cho, SY | 1 |
| Tsai, HL | 1 |
| Smith, BD | 1 |
| Gladstone, DE | 1 |
| Carraway, HE | 1 |
| Huff, CA | 1 |
| Matsui, WH | 1 |
| Bolaños-Meade, J | 1 |
| Jones, RJ | 1 |
| Swinnen, LJ | 1 |
| Risitano, AM | 1 |
| Camera, A | 1 |
| Chiurazzi, F | 1 |
| Rossi, M | 1 |
| D'Arco, AM | 1 |
| Rotoli, B | 1 |
| Watts, RG | 1 |
| Hilliard, LM | 1 |
| Berkow, RL | 1 |
| Oguonu, T | 1 |
| Emodi, I | 1 |
| Kaine, W | 1 |
| Mottl, H | 1 |
| Bajciova, V | 1 |
| Nemec, J | 1 |
| Al Shemmari, S | 1 |
| Al Awadi, S | 1 |
| Mak, YK | 1 |
| Chan, CH | 1 |
| Li, CK | 1 |
| Lee, MP | 1 |
| Tsang, YW | 1 |
| Corbacioglu, S | 1 |
| Eber, S | 1 |
| Gungor, T | 1 |
| Hummerjohann, J | 1 |
| Niggli, F | 1 |
| Belgaumi, AF | 1 |
| Al-Bakrah, M | 1 |
| Al-Mahr, M | 1 |
| Al-Jefri, A | 1 |
| Al-Musa, A | 1 |
| Saleh, M | 1 |
| Salim, MF | 1 |
| Osman, M | 1 |
| Osman, L | 1 |
| El-Solh, H | 1 |
| Bredt, M | 1 |
| Schönfeld, G | 1 |
| Kleeberger, W | 1 |
| König, E | 1 |
| Kröning, H | 1 |
| Kettner, E | 1 |
| Al-Ali, HK | 1 |
| Niederwieser, D | 1 |
| Kreipe, H | 1 |
| Cimino, G | 1 |
| Elia, L | 1 |
| Mancini, M | 1 |
| Annino, L | 1 |
| Anaclerico, B | 1 |
| Fazi, P | 1 |
| Vitale, A | 1 |
| Specchia, G | 1 |
| Di Raimondo, F | 1 |
| Recchia, A | 1 |
| Cuneo, A | 1 |
| Mecucci, C | 1 |
| Pane, F | 1 |
| Saglio, G | 1 |
| Foa, R | 1 |
| Mandelli, F | 1 |
| Sanz, MA | 1 |
| Fernández-Abellán, P | 1 |
| Feliu, E | 1 |
| Waldman, MA | 1 |
| Callen, JP | 1 |
| Bregani, ER | 1 |
| Balzarini, L | 1 |
| Cabibbe, M | 1 |
| Muwakkit, SA | 1 |
| Razzouk, BI | 1 |
| Shabb, NS | 1 |
| Hancock, ML | 1 |
| Dabbous, I | 1 |
| Firzli, S | 1 |
| Abboud, MR | 1 |
| Hesseling, P | 1 |
| Broadhead, R | 1 |
| Mansvelt, E | 1 |
| Louw, M | 1 |
| Wessels, G | 1 |
| Borgstein, E | 1 |
| Schneider, J | 1 |
| Molyneux, E | 1 |
| Xia, Y | 2 |
| Sun, XF | 2 |
| Zhang, CQ | 1 |
| Zhen, ZJ | 2 |
| Wang, ZH | 2 |
| Wang, ZQ | 1 |
| Madani, A | 1 |
| Benhmiddoune, L | 1 |
| Zafad, S | 1 |
| Harif, M | 1 |
| Quessar, A | 1 |
| Benchekroun, S | 1 |
| van Imhoff, GW | 1 |
| van der Holt, B | 1 |
| MacKenzie, MA | 1 |
| Ossenkoppele, GJ | 1 |
| Wijermans, PW | 1 |
| Kramer, MH | 1 |
| van 't Veer, MB | 1 |
| Schouten, HC | 2 |
| van Marwijk Kooy, M | 1 |
| van Oers, MH | 1 |
| Raemaekers, JM | 1 |
| Sonneveld, P | 1 |
| Meulendijks, LA | 1 |
| Kluin, PM | 1 |
| Kluin-Nelemans, HC | 1 |
| Verdonck, LF | 1 |
| Lim, ST | 1 |
| Karim, R | 1 |
| Nathwani, BN | 1 |
| Tulpule, A | 1 |
| Espina, B | 1 |
| Levine, AM | 1 |
| Ogawa, T | 1 |
| Mizutani, M | 1 |
| Yabana, T | 1 |
| Miyahara, S | 1 |
| Murabayashi, K | 1 |
| Vorob'ev, IA | 1 |
| Moiseeva, TN | 1 |
| Zybunova, EE | 1 |
| Lorie, IuIu | 1 |
| Chernova, NG | 1 |
| Egorova, EK | 2 |
| Gabeeva, NG | 1 |
| Boriakh, EA | 1 |
| Shavlokhov, VS | 1 |
| Danishian, KI | 1 |
| Diviné, M | 1 |
| Casassus, P | 1 |
| Sebban, C | 1 |
| Le Maignan, C | 1 |
| Stamattoulas, A | 1 |
| Dupriez, B | 1 |
| Raphaël, M | 2 |
| Pico, JL | 2 |
| Unholzer, A | 1 |
| Starz, H | 1 |
| Hirschsteiner, O | 1 |
| Balda, BR | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Lui, DG | 1 |
| He, YJ | 1 |
| Lin, JY | 1 |
| Guan, ZZ | 1 |
| Friedrichs, B | 1 |
| Tiemann, M | 1 |
| Salwender, H | 1 |
| Verpoort, K | 1 |
| Wenger, MK | 1 |
| Schmitz, N | 1 |
| Kalinyak, JE | 1 |
| Kong, CS | 1 |
| McDougall, IR | 1 |
| Hoffmann, C | 1 |
| Wolf, E | 1 |
| Wyen, C | 1 |
| Fätkenheuer, G | 1 |
| Van Lunzen, J | 1 |
| Stellbrink, HJ | 1 |
| Stoehr, A | 1 |
| Plettenberg, A | 1 |
| Jaeger, H | 1 |
| Noppeney, R | 1 |
| Hentrich, M | 1 |
| Goekbuget, N | 1 |
| Horst, HA | 1 |
| Naithani, R | 1 |
| Chandra, J | 1 |
| Kumar, A | 1 |
| Choudhary, SR | 1 |
| Sharma, S | 1 |
| Patte, C | 2 |
| Auperin, A | 1 |
| Gerrard, M | 3 |
| Michon, J | 2 |
| Pinkerton, R | 1 |
| Sposto, R | 1 |
| Weston, C | 1 |
| McCarthy, K | 1 |
| Chen, R | 1 |
| Abbott, BL | 1 |
| Myint, H | 1 |
| Crosswell, HE | 1 |
| Bergsagel, DJ | 1 |
| Yost, R | 1 |
| Lew, G | 1 |
| Northup, JK | 1 |
| Gadre, SA | 1 |
| Ge, Y | 1 |
| Lockhart, LH | 1 |
| Velagaleti, GV | 1 |
| Italiano, A | 1 |
| Peyrade, F | 1 |
| Soler, C | 1 |
| Cardot, N | 1 |
| Thyss, A | 1 |
| Kujawski, LA | 1 |
| Longo, WL | 1 |
| Williams, EC | 1 |
| Turman, NJ | 1 |
| Brandt, N | 1 |
| Mosher, DF | 1 |
| Eickhoff, JC | 1 |
| Galicier, L | 1 |
| Fieschi, C | 1 |
| Borie, R | 1 |
| Meignin, V | 1 |
| Daniel, MT | 1 |
| Gérard, L | 1 |
| Oksenhendler, E | 1 |
| Blinder, VS | 1 |
| Chadburn, A | 1 |
| Furman, RR | 1 |
| Mathew, S | 1 |
| Leonard, JP | 1 |
| Bogusławska-Jaworska, J | 1 |
| Grześkowiak-Melanowska, J | 1 |
| Kaczmarek, M | 1 |
| Kościelniak, E | 1 |
| Legutko, L | 1 |
| Sońta-Jakimczyk, D | 1 |
| Sroczyńska, M | 1 |
| Wojcik, Z | 1 |
| Dummer, JS | 1 |
| Bound, LM | 1 |
| Singh, G | 1 |
| Atchison, RW | 1 |
| Kapadia, SB | 1 |
| Ho, M | 1 |
| Wilson, JF | 1 |
| Jenkin, DT | 1 |
| Meadows, AT | 2 |
| Kersey, J | 1 |
| Chilcote, RR | 1 |
| Coccia, P | 1 |
| Exelby, P | 1 |
| Kushner, J | 1 |
| Siegel, S | 1 |
| Hammond, D | 1 |
| Schoengen, A | 1 |
| Raman, S | 1 |
| Saeed, SM | 1 |
| Kini, KR | 1 |
| Feltkamp, H | 1 |
| Döhnert, G | 1 |
| Stock, W | 1 |
| Lang, R | 1 |
| Mies, R | 1 |
| Mödder, B | 1 |
| Thiele, KG | 1 |
| Cohen, LF | 1 |
| Balow, JE | 1 |
| Magrath, IT | 1 |
| Poplack, DG | 1 |
| Ziegler, JL | 1 |
| Thomas, X | 1 |
| Archimbaud, E | 1 |
| Charrin, C | 1 |
| Magaud, JP | 1 |
| Fiere, D | 1 |
| Jost, LM | 1 |
| Jacky, E | 1 |
| Dommann-Scherrer, C | 1 |
| Honegger, HP | 1 |
| Maurer, R | 1 |
| Sauter, C | 1 |
| Stahel, RA | 1 |
| Frappaz, D | 1 |
| Leverger, G | 1 |
| Rubie, H | 1 |
| Soussain, C | 1 |
| Finlay, JL | 1 |
| Cecalupo, AJ | 1 |
| Hutchinson, RJ | 1 |
| Kadin, ME | 1 |
| Kjeldsberg, CR | 1 |
| Provisor, AJ | 1 |
| Woods, WG | 1 |
| Kudva, GC | 1 |
| Chandy, M | 1 |
| Dennison, D | 1 |
| Srivastava, A | 1 |
| Bhushan, V | 1 |
| Maluf, PT | 1 |
| Odone Filho, V | 1 |
| Cristofani, LM | 1 |
| Britto, JL | 1 |
| Almeida, MT | 1 |
| Pontes, E | 1 |
| Maksoud, JG | 1 |
| Manissadjian, A | 1 |
| Neumann, Y | 1 |
| Toren, A | 1 |
| Mandel, M | 1 |
| Martinowitz, U | 1 |
| Varon, D | 1 |
| Ramot, B | 2 |
| Ben-Bassat, I | 1 |
| Rechavi, G | 1 |
| Mazza, JJ | 1 |
| Hines, JD | 1 |
| Andersen, JW | 1 |
| Neiman, RS | 1 |
| Mann, R | 1 |
| Oken, MM | 1 |
| O'Connell, MJ | 1 |
| Ludwig, WD | 2 |
| Thiel, E | 1 |
| Gassmann, W | 1 |
| Löffler, H | 1 |
| Fonatsch, C | 1 |
| Rieder, H | 1 |
| Heil, G | 1 |
| Heinze, B | 1 |
| Arnold, R | 1 |
| Hossfeld, D | 1 |
| Büchner, T | 1 |
| Koch, P | 1 |
| Freund, M | 1 |
| Hiddemann, W | 1 |
| Maschmeyer, G | 1 |
| Heyll, A | 1 |
| Aul, C | 1 |
| Faak, T | 1 |
| Kuse, R | 1 |
| Ittel, TH | 1 |
| Gramatzki, M | 1 |
| Diedrich, H | 1 |
| Kolbe, K | 1 |
| Fuhr, HG | 1 |
| Fischer, K | 1 |
| Schadeck-Gressel, C | 1 |
| Weiss, A | 1 |
| Strohscheer, I | 1 |
| Metzner, B | 1 |
| Fabry, U | 1 |
| Gökbuget, N | 1 |
| Völkers, B | 1 |
| Messerer, D | 1 |
| Uberla, K | 1 |
| Vivanco Martínez, JL | 1 |
| García Gscheidle, A | 1 |
| Cela de Julián, ME | 1 |
| Torres Valdivieso, MJ | 1 |
| Melero Moreno, C | 1 |
| López Pérez, J | 1 |
| Contra Gómez, T | 1 |
| Martín Ramos, N | 1 |
| Díaz Pérez, MA | 1 |
| Bernácer Borja, M | 1 |
| Gil López, C | 1 |
| Valverde Moreno, F | 1 |
| Arano, Y | 1 |
| Hirano, M | 1 |
| Murakami, N | 1 |
| Nagao, S | 1 |
| Tabata, S | 1 |
| Ishikawa, N | 1 |
| Kikkawa, H | 1 |
| Masuda, S | 1 |
| Salloum, E | 1 |
| Tallini, G | 1 |
| Levy, A | 1 |
| Cooper, DL | 1 |
| Rubnitz, JE | 1 |
| Shuster, JJ | 1 |
| Land, VJ | 1 |
| Link, MP | 1 |
| Pullen, DJ | 1 |
| Camitta, BM | 1 |
| Pui, CH | 1 |
| Downing, JR | 1 |
| Behm, FG | 1 |
| Brockmeyer, NH | 1 |
| Pohl, G | 1 |
| Mertins, L | 1 |
| Rivera-Luna, R | 1 |
| Cardenas-Cardos, R | 1 |
| Leal-Leal, C | 1 |
| Navarro-Alegría, I | 1 |
| Meza-Coria, C | 1 |
| Gómez-Martínez, R | 1 |
| Vega-Vega, L | 1 |
| Creatsas, GK | 1 |
| Hassan, EA | 1 |
| Deligeoroglou, EK | 1 |
| Markaki, SG | 1 |
| Michalas, SP | 1 |
| Souto, P | 1 |
| Romãozinho, JM | 1 |
| Figueiredo, P | 1 |
| Ferreira, M | 1 |
| Sousa, I | 1 |
| Camacho, E | 1 |
| Donato, A | 1 |
| Freitas, D | 1 |
| Hanazawa, T | 1 |
| Kimura, Y | 1 |
| Sakamaki, H | 1 |
| Yamaguchi, A | 1 |
| Nagumo, M | 1 |
| Okano, T | 1 |
| Lenormand, B | 1 |
| Béné, MC | 1 |
| Lesesve, JF | 1 |
| Bastard, C | 1 |
| Lefranc, MP | 1 |
| Faure, GC | 1 |
| Garand, R | 1 |
| Falkenrodt, A | 1 |
| Kandel, G | 1 |
| Solary, E | 1 |
| Maynadié, M | 1 |
| Callat, MP | 1 |
| Thouret, F | 1 |
| Monconduit, M | 1 |
| Vannier, JP | 1 |
| Atra, A | 2 |
| Hobson, R | 2 |
| Imeson, JD | 2 |
| Ashley, S | 1 |
| Pinkerton, CR | 2 |
| Dubern, B | 1 |
| Alessandri, JL | 1 |
| Montbrun, A | 1 |
| Attali, T | 1 |
| Pilorget, H | 1 |
| Samperiz, S | 1 |
| Ferguson, WS | 1 |
| Tutor-Ureta, O | 1 |
| Díaz, MA | 1 |
| Algara, P | 1 |
| Madero, L | 1 |
| Martínez, P | 1 |
| Obeid, L | 1 |
| Schär, B | 1 |
| Heitzmann, F | 1 |
| Bargetzi, M | 1 |
| Dubey, SP | 1 |
| Sengupta, SK | 1 |
| Kaleh, LK | 1 |
| Morewaya, JT | 1 |
| Kaiser, U | 1 |
| Uebelacker, I | 1 |
| Havemann, K | 1 |
| Smets, F | 1 |
| Vajro, P | 1 |
| Cornu, G | 1 |
| Reding, R | 1 |
| Otte, JB | 1 |
| Sokal, E | 1 |
| Manganaro, AM | 1 |
| Phillips, KM | 1 |
| Silfen, ME | 1 |
| Garvin, JH | 1 |
| Hays, AP | 1 |
| Starkman, HS | 1 |
| Aranoff, GS | 1 |
| Levine, LS | 1 |
| Feldstein, NA | 1 |
| Wong, B | 1 |
| Oberfield, SE | 1 |
| Dunphy, CH | 1 |
| Hann, IM | 1 |
| Cohen, Y | 1 |
| Amir, G | 1 |
| Rachmilewitz, EA | 1 |
| Polliack, A | 1 |
| Harris, E | 1 |
| Jackson, N | 1 |
| Jones, L | 1 |
| Mahendra, P | 1 |
| Hoffmeier, A | 1 |
| Semik, M | 1 |
| Schmid, Ch | 1 |
| Mesters, RM | 1 |
| Castrucci, M | 1 |
| Baba, HA | 1 |
| Fallenberg, EM | 1 |
| Scheld, HH | 1 |
| Carli, P | 1 |
| Gisserot, O | 1 |
| Landais, C | 1 |
| Crémades, S | 1 |
| Paris, JF | 1 |
| de Jauréguiberry, JP | 1 |
| Schmidt, CG | 2 |
| Magrath, I | 1 |
| Henle, W | 1 |
| Owor, R | 1 |
| Olweny, C | 1 |
| Sieber, SM | 1 |
| Kim, E | 1 |
| Herman, T | 1 |
| Hartmann, D | 1 |
| Wegmann, W | 1 |
| Obrecht, JP | 1 |
| Arseneau, JC | 2 |
| Canellos, GP | 2 |
| Banks, PM | 1 |
| Berard, CW | 1 |
| Gralnick, HR | 1 |
| DeVita, VT | 3 |
| Reiter, A | 1 |
| Schrappe, M | 1 |
| Lampert, F | 1 |
| Harbott, J | 1 |
| Henze, G | 1 |
| Niemeyer, CM | 1 |
| Gadner, H | 1 |
| Müller-Weihrich, S | 1 |
| Ritter, J | 1 |
| Crist, W | 1 |
| Shuster, J | 1 |
| Look, T | 1 |
| Borowitz, M | 1 |
| Behm, F | 1 |
| Bowman, P | 1 |
| Frankel, L | 1 |
| Pullen, J | 1 |
| Krance, R | 1 |
| Steuber, P | 1 |
| Bomfim da Paz, R | 1 |
| Kölmel, HW | 1 |
| Yih, WY | 1 |
| Myers, SL | 1 |
| Meshul, CK | 1 |
| Bartley, MH | 1 |
| Bader-Meunier, B | 1 |
| Garel, D | 1 |
| Dommergues, JP | 1 |
| Venencie, PY | 1 |
| Kath, R | 1 |
| Höffken, K | 1 |
| Günzel, K | 1 |
| Nowrousian, MR | 1 |
| Donhuijsen, K | 1 |
| Anders, CU | 1 |
| Sack, H | 1 |
| Klassen, LW | 1 |
| Vaughan, WP | 1 |
| Weisenburger, D | 1 |
| Kessinger, A | 1 |
| Cuzick, J | 1 |
| Cubells Riero, J | 1 |
| Pardo García, N | 1 |
| Turmo Martí, J | 1 |
| Vela Ferrer, E | 1 |
| Badía Torroella, RM | 1 |
| González Rivero, MA | 1 |
| Illa Sala, J | 1 |
| Melo Valls, M | 1 |
| Matsuoka, T | 1 |
| Yoshimoto, S | 1 |
| Sonobe, H | 1 |
| Kiyoku, Y | 1 |
| Yamasaki, M | 1 |
| Taguchi, H | 1 |
| Miyoshi, I | 1 |
| Bernstein, JI | 1 |
| Coleman, CN | 1 |
| Strickler, JG | 1 |
| Dorfman, RF | 1 |
| Rosenberg, SA | 1 |
| Dabich, L | 1 |
| Ensminger, WD | 1 |
| Zuckerman, KS | 1 |
| Wheeler, RH | 1 |
| LoBuglio, AF | 1 |
| Song, SZ | 1 |
| Real, FX | 1 |
| Krown, SE | 1 |
| Koziner, B | 1 |
| Gómez Campderá, FJ | 1 |
| López Gómez, JM | 1 |
| Delgado, J | 1 |
| Ramos, M | 1 |
| Morales, JL | 1 |
| Lugue, A | 1 |
| Gómez Campderá, J | 1 |
| Mathé, G | 1 |
| Schwarzenberg, L | 1 |
| Amiel, JL | 1 |
| Schneider, M | 1 |
| Cattan, A | 1 |
| Schlumberger, JR | 1 |
| Zubrod, CG | 1 |
| Jaffe, N | 1 |
| Traggis, D | 1 |
| Das, L | 1 |
| Moloney, WC | 1 |
| Hann, HW | 1 |
| Kim, BS | 1 |
| Nair, R | 1 |
| Aghai, E | 1 |
| Hulu, N | 1 |
| Virag, I | 1 |
| Kende, G | 1 |
| Burchenal, JH | 1 |
| Dowling, MD | 1 |
| Cole, MT | 1 |
| Carbone, PP | 2 |
| Rubin, P | 1 |
| Rodriguez, V | 2 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| Sherins, RJ | 2 |
| Pevzner, S | 1 |
| Leef, F | 1 |
| Frei, E | 1 |
| Dunnick, NR | 1 |
| Cunningham, JJ | 1 |
| McElwain, TJ | 1 |
| Ravina, A | 1 |
| Condit, PT | 1 |
| Gutterman, J | 1 |
| McMullan, G | 1 |
| Holland, JF | 1 |
| Rall, DP | 1 |
| Henderson, ES | 1 |
| White, LP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma[NCT01092182] | Phase 2 | 194 participants (Actual) | Interventional | 2010-03-25 | Completed | ||
| A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk)[NCT00974792] | Phase 2 | 150 participants (Anticipated) | Interventional | 2006-01-31 | Recruiting | ||
| Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas[NCT00006436] | Phase 2 | 68 participants (Actual) | Interventional | 2001-01-29 | Active, not recruiting | ||
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma[NCT00001337] | Phase 2 | 348 participants (Actual) | Interventional | 1993-05-08 | Active, not recruiting | ||
| [NCT00180882] | Phase 3 | 260 participants | Interventional | 2004-10-31 | Recruiting | ||
| Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma[NCT00133991] | Phase 2 | 23 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study[NCT00002757] | Phase 3 | 1,148 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The predictive value of early FDG-PET/CT scans on PFS was assessed after cycle 2. PFS is the time interval from start of treatment to documented evidence of disease progression, assessed by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: After 2 cycles of therapy and prior to cycle 3
| Intervention | percentage of participants (Number) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 100 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 90.0 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 78.7 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01092182)
Timeframe: Date treatment consent signed to date off study, approximately 102 months and 25 days for Group A, 125 months and 28 days for Group B and 117 months and 29 days for group C.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 13 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 87 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 72 |
OS was calculated from the enrolment date until date of death or last follow-up using the Kaplan Meier. Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: At 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 100 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 84.9 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 76.7 |
EFS was determined from the date of enrolment in the study until the date of progression, last documentation of disease at or after the last treatment cycle, death, or last follow-up (whichever occurred first). Disease progression was measured by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: At 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 100 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 82.1 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 71.0 |
PFS is the time interval from start of treatment to documented evidence of disease progression. Disease progression was measured by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: Time of progression or death at 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 100 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 82.1 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 71.0 |
Overall survival is time from treatment start date until date of death or date last known alive. (NCT00006436)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 83.7 |
"Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy).~Complete response unconfirmed (CRu) is when a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by > 75% in sum of the products of the greatest diameters or are < 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR." (NCT00006436)
Timeframe: The participants were followed for duration of complete response or complete response unconfirmed for a median of 15.4 years.
| Intervention | years (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 13.9 |
Overall survival is time from treatment start date until date of death or date last known alive. (NCT00006436)
Timeframe: The participants were followed for survival for a median of 15.4 years.
| Intervention | years (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 14.2 |
PFS is the time interval from study entry to documented evidence of disease progression or death due to any cause. Progression is defined according to the Cheson response criteria. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). Confidence intervals were made, and a Kaplan-Meier curve of progression free survival was constructed. (NCT00006436)
Timeframe: The participants were followed for a median of 15.4 years.
| Intervention | years (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 13.8 |
Toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Febrile neutropenia is defined as a life-threatening complication requiring hospitalization and urgent broad-spectrum antibiotics. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 18 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 66 |
Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy). (NCT00006436)
Timeframe: The participants were followed for an average of 6 months to determine response to therapy.
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 95 |
"Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy).~Complete response unconfirmed (CRu) is when a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by > 75% in sum of the products of the greatest diameters or are < 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR." (NCT00006436)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 82.5 |
PFS is the time interval from start of treatment to documented evidence of disease progression. Progression is defined according to the Cheson response criteria. Disease progression as indicated by imaging scans at one year following therapy. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). (NCT00006436)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 79.1 |
Participants with human immunodeficiency virus (HIV) who undergo chemotherapy may have a delay in the recovery of their normal CD4+ T-cells. This delay could result in an increased risk of infection. Recovery of CD4 cells counts is the time from end of therapy until the time that the CD4 counts first reached above 200 cells/uL. (NCT00006436)
Timeframe: From the end of chemotherapy every 3 months for the first 2 years
| Intervention | months (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 2.5 |
The HIV viral load is a measure of actively replicating virus in the blood. If no anti-retroviral therapy is given, then reduction of this HIV viral load to manageable levels might risk infection. In our study, the recovery of HIV viral load was measured the time from the initiation of antiretroviral therapy until the viral load was undetectable or < 50 copies. (NCT00006436)
Timeframe: Either following or concurrently with combination chemo and biological therapy, approximately every 6 to 8 weeks after therapy was completed up to 16 months
| Intervention | months (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 2 |
"1-year PFS is defined as participants who remain free of disease progression or death at one year from study entry. We compared the 1-year PFS of participants with negative results on interim positron emission tomography (PET) scans to those with positive results on interim PET scans.~PFS is defined as the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival." (NCT00006436)
Timeframe: 1 year
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Interim PET scan positive 1-year PFS | Interim PET scan negative 1 year PFS | |
| Arm 1-Combination Chemo and Biological Therapy | 61.5 | 89.3 |
PFS is the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles (each cycle is 21 days + 7 days window) of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival. (NCT00006436)
Timeframe: Participants were followed for up to 10.2 years to determine their response on interim PET scans.
| Intervention | years (Median) | |
|---|---|---|
| Interim PET positive participants | Interim PET negative participants | |
| Arm 1-Combination Chemo and Biological Therapy | 10.2 | NA |
Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). (NCT00006436)
Timeframe: Up to 112 cycles (each cycle is 21 days + 7 days window)
| Intervention | cycles (Number) | |||||
|---|---|---|---|---|---|---|
| Febrile neutropenia | Neutropenia with a Nadir <500 cells/mm^3 | Neutropenia with a Nadir <100 cells/mm^3 | Thrombocytopenia with a Nadir <50,000 platelets/mm^3 | Thrombocytopenia with a Nadir <25,000 platelets/mm^3 | Anemia: hemoglobin <8 g/dL | |
| Arm 1-Combination Chemo and Biological Therapy | 25 | 112 | 77 | 40 | 6 | 36 |
Non-hematologic (i.e., not begin in bone marrow or blood) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serious infection | Neurologic event | Syncope | Confusion | Motor neuropathy | Vision disturbance | Hyperglycemia | Hypophosphatemia | Hypocalcemia | Hypokalemia | Hyponatremia | Dehydration | Mucositis/Stomatitis | Liver test abnormalities | Pancreatitis | Diarrhea | Constipation | Serious hemorrhage | Fatigue | Headache | Bone pain | Nausea | Anorexia | Hypoxia | Myelodysplastic syndrome | |
| Grade 3 | 17 | 0 | 1 | 1 | 0 | 1 | 4 | 2 | 2 | 1 | 1 | 1 | 6 | 6 | 1 | 2 | 1 | 5 | 2 | 5 | 1 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 4 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Overall response was determined by the Cheson Response Criteria. Participants with either a complete response (CR), complete response unconfirmed or partial response were considered responders. Less than a partial response was considered a non-response to therapy (i.e., Stable Disease and/or Progressive Disease). Complete response was defined as the disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size. Complete response unconfirmed is a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. Partial response is defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measured lesions lasting for a period of at least one month. (NCT00006436)
Timeframe: The participants were followed for an average of 6 months to determine response to therapy.
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete Response | Complete Response Unconfirmed | Partial Response | Non-Responder - Stable Disease | Non-Responder - Progressive Disease | |
| Arm 1-Combination Chemo and Biological Therapy | 53 | 10 | 1 | 1 | 1 |
Percentage of participants experiencing at least one grade 3-5 adverse event (by CTCAE 3.0 criteria). (NCT00133991)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| R-CVP + HiCy | 21 |
Percentage of participants alive without relapse at 1 year and 3 years. (NCT00133991)
Timeframe: 1 year and 3 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 3 years | |
| R-CVP + HiCy | 52 | 52 |
Number of participants who have a complete or partial remission (2007 International Working Group criteria). (NCT00133991)
Timeframe: Up to 3 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete remission | Partial remission | |
| R-CVP + HiCy | 11 | 2 |
Percentage of participants alive at 1 year and at 3 years. (NCT00133991)
Timeframe: 1 year and 3 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 3 years | |
| R-CVP + HiCy | 57 | 57 |
Percentage of participants experiencing central nervous system (CNS) and systemic relapse. (NCT00133991)
Timeframe: Up to 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Systemic relapse only | Systemic and CNS relapse | |
| R-CVP + HiCy | 3 | 2 |
24 reviews available for prednisone and African Lymphoma
| Article | Year |
|---|---|
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2017 |
[MYC-associated B-cell lymphomas: pathophysiology and treatment].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2019 |
Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2013 |
Adult abdominal Burkitt lymphoma with isolated peritoneal involvement.
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carcinoma; Cyclophosphami | 2014 |
[Treatment strategy of gray zone lymphomas].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2014 |
Case report and review of immunodeficiency-associated Burkitt lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 2015 |
[Recent advances and the treatment strategies of AIDS-related malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Adult Burkitt lymphoma: advances in diagnosis and treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2008 |
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2012 |
HIV-associated lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2012 |
Post-transplant Burkitt's leukemia or lymphoma. Study of five cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cyt | 2003 |
Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate.
Topics: Biopsy; Brain Neoplasms; Burkitt Lymphoma; Dermatomyositis; Humans; Immunosuppressive Agents; Magnet | 2004 |
Improving outcomes for patients with Burkitt lymphoma and HIV.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2008 |
[Isolated tumor of the rectum as primary manifestation of Burkitt lymphoma (author's transl)].
Topics: Adult; Burkitt Lymphoma; Doxorubicin; Female; Humans; Lymphatic Metastasis; Prednisone; Prognosis; R | 1981 |
Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Ly | 1994 |
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1996 |
Burkitt's lymphoma involving the mandible: report of a case and review of Japanese cases.
Topics: Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplast | 1998 |
The action of antitumor agents: a double-edged sword?
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azathioprine; Burkitt Lymphoma; Choriocarcinoma; | 1977 |
[Advances in the chemotherapy of non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modality The | 1985 |
Non-Hodgkin's lymphoma: recent observations on natural history and intensive treatment.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Follow-Up Studies; Humans; Lymphoma; Lymp | 1972 |
Combination chemotherapy for lymphomas and leukemias.
Topics: Adult; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; Hodgk | 1973 |
Recently recognized complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Death, Sudden; Drug Therapy, Combination; | 1974 |
[Burkitt's lymphoma and acute leukemias].
Topics: Acute Disease; Animals; Asparaginase; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Dactino | 1969 |
Chemotherapy of neoplastic disease with folate antagonists.
Topics: Acute Disease; Administration, Oral; Adult; Age Factors; Body Weight; Burkitt Lymphoma; Carcinoma, S | 1971 |
23 trials available for prednisone and African Lymphoma
| Article | Year |
|---|---|
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2020 |
Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series.
Topics: Adult; Aged; Allografts; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2018 |
Low-intensity therapy in adults with Burkitt's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2013 |
Low-intensity therapy in adults with Burkitt's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2013 |
Low-intensity therapy in adults with Burkitt's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2013 |
Low-intensity therapy in adults with Burkitt's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2013 |
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Neoplasm | 2016 |
[Efficacy of conservative treatment of gastric lymphosarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymph | 2008 |
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineopl | 2003 |
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2005 |
Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2005 |
Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2006 |
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 2007 |
A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Dox | 2007 |
Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Burkit | 2007 |
Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2).
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; | 1983 |
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1995 |
Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1994 |
Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's undifferentiated lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 1995 |
Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bioma | 1997 |
B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 1997 |
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bur | 1998 |
Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; C | 1998 |
Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymph | 1992 |
144 other studies available for prednisone and African Lymphoma
| Article | Year |
|---|---|
Primary chest wall Burkitt lymphoma in a case of HIV infection with immune reconstitution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Eto | 2021 |
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2022 |
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2023 |
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2023 |
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2023 |
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2023 |
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Hum | 2023 |
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty.
Topics: Adult; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Activ | 2020 |
Rituximab and intense chemotherapy in a patient with defective cell mediated immunity due to cartilage-hair hypoplasia and Burkitt lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxo | 2020 |
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2020 |
Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Eto | 2020 |
Reply to M. Hertzberg et al.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 2020 |
DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 2020 |
Clinical profile, outcome and challenges in the management of pediatric Burkitt lymphoma: a single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; C | 2021 |
Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cycloph | 2021 |
Treatment results of modified BFM protocol in pediatric high-risk Burkitt lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Daunorubicin; | 2021 |
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bio | 2017 |
Skin involvement in Burkitt's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Cyclophosphamide; Doxorubic | 2018 |
Successful Use of EPOCH-R in 2 Young Adult Patients With Burkitt Lymphoma and Acute Kidney Injury: A Case Report.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2019 |
Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt L | 2019 |
Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modality Therapy; | 2014 |
Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Cel | 2014 |
[Treatment outcome in primary testicular non-Hodgkin lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
[B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 2013 |
A rare cause of gastric malignancy: Burkitt's lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burki | 2013 |
[Primary cutaneous follicle centre lymphoma: report of a case].
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; CD79 Antigens; Cyc | 2013 |
Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Oral extranodal non Hodgkin's lymphoma: series of forty two cases in Malaysia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2014 |
Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Antibodies, Monoclonal, Murine-De | 2014 |
Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; C | 2014 |
How I treat Burkitt lymphoma in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabin | 2014 |
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2015 |
Dose-adjusted EPOCH-R for Burkitt lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2014 |
Pediatric B-cell lymphoma, unclassifiable, with intermediate features between those of diffuse large B-cell lymphoma and Burkitt lymphoma: a report of two cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child, Preschool; Cycl | 2015 |
Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adolescent; Adult; Aged; Antineoplastic Combined Che | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
[Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Arthritis, Rheumatoid; Burkitt | 2016 |
[Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabin | 2016 |
Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi.
Topics: Age Factors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child | 2016 |
Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy?
Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2017 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydr | 2016 |
Circulating lymphoma cells of double-hit lymphoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclo | 2016 |
Pancreatic lymphoma complicating early stage chronic hepatitis C.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 2017 |
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2017 |
Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2008 |
Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabin | 2009 |
Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2009 |
[Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Burkit | 2010 |
Burkitt's lymphoma in a young Brazilian boy.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brazil; Burkitt L | 2010 |
Treatment of pediatric Burkitt lymphoma in Turkey.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biops | 2010 |
A rapidly growing lymphoma and tumor lysis syndrome in a toddler.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; C | 2010 |
Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Dox | 2011 |
Human immunodeficiency virus-associated Burkitt's lymphoma in oral cavity of Japanese patient.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Ant | 2012 |
Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis
Topics: Adult; Aged; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2012 |
[Clinicopathological and molecular genetic characteristics of childhood diffuse large B cell lymphoma].
Topics: Adolescent; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; | 2012 |
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infec | 2002 |
Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Chemotherap | 2002 |
Epidemiology of Burkitt's lymphoma in Enugu, Nigeria.
Topics: Adolescent; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Chil | 2002 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 2003 |
Clinical profiles of human immunodeficiency virus-associated lymphoma in Hong Kong.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Ac | 2003 |
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; | 2003 |
Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Asparaginase; Burkitt Lymp | 2003 |
Late-onset Epstein-Barr virus (EBV)-negative extranodal B-precursor lymphoblastic lymphoma of donor origin after hematopoietic stem cell transplantation (HSCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 2003 |
African Burkitt lymphoma successfully treated with CEOP polychemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Cyclophosphamide; Epirubici | 2004 |
Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: a single institution's experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2004 |
The 2000 Burkitt lymphoma trial in Malawi.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agent | 2005 |
[Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2004 |
[Treatment of childhood Burkitt lymphoma according to LMB89 protocol in Casablanca].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2005 |
AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomy | 2005 |
A Case of Burkitt's Lymphoma Involving Both Breasts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Burkitt Lymphoma; Cyclophos | 2005 |
[Treatment of adult Berkitt-like lymphoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2005 |
[Primary gastric lesion in Berkitt-like lymphoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Burkitt Lymphoma; Cycloph | 2005 |
[Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Burkitt Lymphoma; Cyclophosphamide; D | 2005 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
The effects of rituximab treatment during pregnancy on a neonate.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2006 |
Burkitt's lymphoma presenting as a rapidly growing thyroid mass.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Bone Marrow; Burkitt Lymphoma; | 2006 |
AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Burkit | 2006 |
Simultaneous occurrence of Wilms tumor and Burkitt lymphoma in two brothers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child, Preschool; Cyclophosphamide | 2007 |
Treatment of HIV-associated Burkitt Lymphoma in the presence of severe hepatic dysfunction.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 2006 |
Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; | 2008 |
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
Conventional dose intensive immunochemotherapy regimen in an adult patient with very late relapse of Burkitt's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
[Preliminary therapeutic results of treatment of non-Hodgkin lymphoma in children according to the BACOP program].
Topics: Adolescent; Bleomycin; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Dru | 1980 |
Epstein-Barr virus-induced lymphoma in a cardiac transplant recipient.
Topics: Acyclovir; Adult; Burkitt Lymphoma; Cyclosporins; Heart Transplantation; Herpesvirus 4, Human; Human | 1984 |
[Chemotherapy of non-Hodgkin lymphomas].
Topics: Adult; Burkitt Lymphoma; Child; Cyclophosphamide; Drug Therapy, Combination; Humans; Leukemia, Hairy | 1980 |
Acute Burkitt's leukemia: case report and literature review.
Topics: Adolescent; Bone Marrow; Burkitt Lymphoma; Child; Child, Preschool; Female; Histiocytes; Humans; Leu | 1982 |
Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamid | 1980 |
CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Aneuploidy; Antibiotics, Antineoplastic; Antigens, CD; Antigens, | 1995 |
Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymph | 1994 |
Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophos | 1994 |
Favorable response of pediatric AIDS-related Burkitt's lymphoma treated by aggressive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 1993 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1996 |
[The results of treatment by the Madrid Pediatric Oncology Group according to the BFM protocols in non-Hodgkin's B-cell lymphoma and acute B-cell lymphoblastic leukemia in pediatric patients].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; C | 1996 |
[A case report of primary Burkitt lymphoma of the rectum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modality Therapy; Cycloph | 1996 |
Combination of chemotherapy and antiviral therapy for Epstein-Barr virus-associated non-Hodgkin's lymphoma of high grade malignancy in cases of HIV infection.
Topics: Acyclovir; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; Burki | 1997 |
Non-Hodgkin's ovarian lymphoma during adolescence: report of two cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Combined Mo | 1997 |
Severe acute liver failure as the initial manifestation of haematological malignancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Burkitt Lymphoma; Cyclophosphami | 1997 |
[Reye syndrome in a child having received chemotherapy].
Topics: Abdominal Neoplasms; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Ag | 1998 |
From twisted ankles.
Topics: Ankle Injuries; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cast | 1999 |
[The presence of minimal residual disease during induction therapy is a reliable factor for the prognosis of recurrence in children with standard-risk B-cell precursor acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Cyclophospham | 1999 |
[Burkitt's lymphoma--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1999 |
Adult head and neck lymphomas in Papua New Guinea: a retrospective study of 70 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modali | 1999 |
Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 1999 |
Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineopl | 2000 |
Rapidly growing periodontal enlargement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Diagnosis | 2000 |
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cyta | 2001 |
Correspondence re: Viswanatha DS, Foucar K, Berry BR, Gascoyne RD, Evans HL, Leith CP. Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma. Mod Pathol 2000;13:825-33.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Flow Cytometry; | 2001 |
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Child | 2001 |
Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
Burkitt's lymphoma: single-centre experience with modified BFM protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2002 |
[Primary Burkitt lymphoma of the heart--diagnosis and therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Chemother | 2002 |
[A patient with febrile and lymphatic hyperalgesia on returning from the tropics].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Fem | 2002 |
[Chemotherapy in non-Hodgkin's lymphomas (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Burkitt Lymphoma; Chlorambucil; Cyclophosphamide; Doxorubicin; Dru | 1977 |
Antibodies to Epstein-Barr-virus antigens before and after the development of Burkitt's lymphoma in a patient treated for Hodgkin's disease.
Topics: Antibodies, Viral; Antigens, Viral; Burkitt Lymphoma; Child; Herpesvirus 4, Human; Hodgkin Disease; | 1975 |
Burkitt's lymphoma in an American youth: usefulness of radionuclide imaging in diagnosis and measuring the effects of treatment.
Topics: Adolescent; Burkitt Lymphoma; Cyclophosphamide; Humans; Liver Neoplasms; Male; Methotrexate; Pancrea | 1977 |
[The so-called white Burkitt's lymphoma].
Topics: Adolescent; Africa; Burkitt Lymphoma; Gastrointestinal Neoplasms; Humans; Jaw Neoplasms; Male; Predn | 1976 |
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival.
Topics: Abdomen; Adolescent; Adult; Africa, Eastern; Antineoplastic Agents; Burkitt Lymphoma; Child; Child, | 1975 |
Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1992 |
Meningitis with Burkitt like B-cell lymphoma in HIV infection.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 1992 |
African Burkitt's lymphoma: case report and light and electron microscopic findings.
Topics: Africa; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Cyclophosphamide; D | 1990 |
[Transverse leukonychia and anti-leukemia chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child, Preschool; Cyclophosphamide | 1990 |
[Chemotherapy of nonendemic Burkitt's lymphoma].
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Burkitt Lymphoma; Combined Modality Therapy; | 1990 |
Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1989 |
A method for analysing case-control studies with ordinal exposure variables.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biometry; Burkitt Lymphoma; Cl | 1985 |
[Non-Hodgkin's lymphomas in childhood. Evaluation of therapeutic results according to histopathologic criteria (Catalan Interhospital Group of Pediatric Oncology)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophos | 1988 |
[Long-term survival of two patients with Burkitt's lymphoma treated by surgical resection and intensive chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Burkitt Lymphoma; Cecal Neo | 1988 |
Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).
Topics: Abdominal Neoplasms; Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemothera | 1986 |
High-dose adriamycin combination chemotherapy for intermediate and high-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cyt | 1985 |
Steroid-related development of Kaposi's sarcoma in a homosexual man with Burkitt's lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt L | 1986 |
[Burkitt's lymphoma and tumor lysis syndrome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child, Preschool; Cyclophosphamide | 1985 |
The role of immunology in the treatment of leukemias and hematosarcomas.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Burkitt Lymphoma; gamma-Globulins; Huma | 1967 |
Acute leukemias and Burkitt's lymphoma. Present status of therapy.
Topics: Antineoplastic Agents; Asparaginase; Burkitt Lymphoma; Choriocarcinoma; Cyclophosphamide; Cytarabine | 1968 |
L-asparaginase in the treatment of neoplastic diseases in children.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow Examination; Bone Neoplasms; Burkitt Ly | 1971 |
Childhood non-Hodgkin's lymphoma--a study of 17 cases in Israel.
Topics: Abdominal Neoplasms; Adolescent; Age Factors; Allopurinol; Antigens, Viral; Arabia; Bone Marrow Dise | 1974 |
Eventual control of clinical leukemia.
Topics: Administration, Oral; Africa; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Daunorubicin; Drug The | 1973 |
Management of patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Lymphography; Ly | 1973 |
Updated Hodgkin's disease. C. Advanced disease and special problems. Comment: the non-Hodgkin's lymphomas.
Topics: Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Large B-C | 1973 |
Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Biopsy; Burkitt Lymphoma; Cyclophosphamide; Germ Cells; Ho | 1973 |
Childhood abdominal lymphoma in two brothers.
Topics: Abdominal Neoplasms; Burkitt Lymphoma; Child, Preschool; Cyclophosphamide; Humans; Intestinal Neopla | 1973 |
Status and perspectives in chemotherapy of Hodgkin's disease.
Topics: Animals; Antineoplastic Agents; Benzoates; Breast Neoplasms; Burkitt Lymphoma; Cyclophosphamide; Cyt | 1973 |
Burkitt's lymphoma involving the kidney: urographic findings before and after therapy in an American child.
Topics: Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Humans; Kidney Neoplasms; Male; Prednisone; U | 1974 |
Chemotherapy of the lymphomas.
Topics: Adult; Burkitt Lymphoma; Child; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1974 |
Remission induction of acute leukemia developing in Burkitt's lymphoma.
Topics: Adult; Blood Cells; Bone Marrow Cells; Burkitt Lymphoma; Cyclophosphamide; Drug Combinations; Humans | 1972 |
Summary: recent advances in the treatment of acute leukemia and Burkitt's tumor.
Topics: Antineoplastic Agents; Asparaginase; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Daunorubicin; H | 1967 |
Selective aspects of chemotherapy in acute leukemia and Burkitt's tumor.
Topics: Alkylating Agents; Antimetabolites; Antineoplastic Agents; Bone Marrow; Burkitt Lymphoma; Digestive | 1968 |
Treatment of acute leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Burkitt Lymphoma; Child; Child, Prescho | 1968 |
Leukemia and lymphoma.
Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cyta | 1970 |